Clascoterone, marketed under the brand name Winlevi, became a medical milestone on August 26, 2020, when the FDA approved it as the first topical antiandrogen specifically designed to treat acne vulgaris. What makes this approval historically significant is that it marked the first FDA-approved acne medication with a novel, first-in-class mechanism of action in nearly 40 years—and critically, it’s the first topical antiandrogen approved for use in both men and women. If you’ve been struggling with hormonally-driven acne, whether you’re a teenage girl dealing with breakouts during your menstrual cycle or an adult man experiencing persistent comedones along your jawline, clascoterone offers a targeted treatment option that didn’t exist in topical form before.
The drug is approved for patients aged 12 years and older, making it available to adolescents and adults across both sexes. This approval followed rigorous clinical testing in over 1,400 subjects with acne vulgaris, demonstrating that clascoterone worked equally well regardless of patient gender, age, or ethnicity. For the first time, dermatologists and patients had a topical treatment that could directly block androgen hormones at the skin level—the underlying driver of acne in many people—rather than simply targeting the symptoms.
Table of Contents
- What Is an Antiandrogen and How Does Clascoterone Target Acne at Its Source?
- The Clinical Evidence: What Two Major Trials Revealed
- Breaking Down the Clinical Trial Results
- Safety and Side Effects: A Surprisingly Mild Adverse Event Profile
- The Cost Reality: Significant Financial Barrier to Access
- Global Rollout: From FDA Approval to International Availability
- Who Should Consider Clascoterone, and What Does the Future Hold?
- Conclusion
What Is an Antiandrogen and How Does Clascoterone Target Acne at Its Source?
Androgens are hormones that fuel sebaceous glands and contribute to acne formation. While androgens are essential for normal development and function, excess androgen activity in the skin can trigger increased sebum production, clogged pores, and the proliferation of acne-causing bacteria. Traditional topical acne treatments like benzoyl peroxide and retinoids work by killing bacteria, reducing inflammation, or promoting skin cell turnover—they address the consequences of acne but not the hormonal driver itself. Clascoterone takes a fundamentally different approach by acting as a topical antiandrogen, blocking androgens directly in the skin without requiring systemic hormonal changes.
The distinction is important. Systemic antiandrogens like spironolactone work throughout the entire body by interfering with hormone levels, which can be effective but carries potential systemic side effects and requires blood work monitoring. Clascoterone, by contrast, works locally where applied. It’s delivered directly to the skin and sebaceous glands, suppressing androgen receptors in those tissues without entering the bloodstream in significant quantities. For a patient with acne primarily localized to the face or chest, this targeted approach means symptom relief with minimal systemic exposure—similar to how topical corticosteroids deliver potent effects in a limited area without the side effects associated with oral steroids.
The Clinical Evidence: What Two Major Trials Revealed
The FDA’s approval of clascoterone was based on two Phase 3 randomized controlled trials that enrolled a combined 1,440 subjects ages 9 and older with moderate acne vulgaris. These were rigorous, placebo-controlled studies—the gold standard for evaluating new medications. In both trials, clascoterone cream 1% demonstrated superiority over vehicle (placebo) on all primary endpoints. By week 12 of treatment, participants using clascoterone showed significantly larger reductions in inflammatory lesion counts, non-inflammatory lesion counts, and total lesion counts compared to those using placebo.
The consistency of results across both trials strengthened confidence in the drug’s efficacy. One notable finding was that efficacy did not differ meaningfully between male and female patients, nor between different age groups or ethnic backgrounds. This universality of effect was crucial for approval as a treatment suitable for both sexes. However, it’s important to recognize that “moderate acne” was the population studied—patients with very mild acne or severe cystic acne may have different outcomes. Additionally, the trials lasted 12 weeks; long-term efficacy data spanning months or years of continuous use is more limited, though available data suggests sustained benefit with ongoing application.
Breaking Down the Clinical Trial Results
The Phase 3 trials measured three main outcomes: inflammatory lesion count, non-inflammatory lesion count (blackheads and whiteheads), and total lesion count. Across both trials, clascoterone achieved statistically significant and clinically meaningful reductions. Participants in the treatment groups typically saw their lesion counts drop by approximately 40-50% by week 12—a substantial improvement that translates to visible clearing of acne. To put this in perspective, if someone started treatment with 30 inflammatory acne lesions on their face, they could reasonably expect to see that number drop to 15 or fewer by the end of 12 weeks, assuming consistent application and no other confounding factors.
The trials also enrolled younger subjects (ages 9+), which is unusual for acne studies and reflects clascoterone’s safety profile in pediatric populations. Real-world usage, however, is approved starting at age 12. One practical limitation: the trials used clascoterone as monotherapy (a single treatment), so the studies don’t provide direct comparisons to combination therapy—for example, using clascoterone alongside benzoyl peroxide or adapalene, which many dermatologists might recommend for optimal results. Patients in clinical practice often benefit from a multi-modal approach, but the label data comes specifically from clascoterone alone.
Safety and Side Effects: A Surprisingly Mild Adverse Event Profile
When evaluating any new medication, the side effect profile is paramount. Clascoterone’s safety data is notably reassuring compared to some other acne treatments. The most frequently reported adverse reactions were local skin irritation, with erythema (redness), pruritus (itching), and scaling or dryness occurring in 7-12% of users. For context, benzoyl peroxide commonly causes dryness, peeling, and irritation in 20-30% of users, while topical retinoids like tretinoin cause these effects in up to 40% of patients during the initial weeks of use. Clascoterone’s irritation rate is considerably lower.
What’s particularly striking is the absence of certain side effects that plague other acne treatments. Patients reported essentially no peeling, severe dryness, redness, or swelling when using clascoterone as directed—a major advantage over retinoids, which frequently cause these issues. Patient-reported stinging and burning were minimal to none. The most common complaint was mild itching or slight redness at the application site, which typically resolves within days. Importantly, clascoterone did not cause systemic hormonal effects in the studies—no changes in testosterone levels, menstrual cycles, or other endocrine markers. However, the drug is not recommended for use during pregnancy due to limited data, and nursing mothers should avoid applying it to areas where an infant might make contact during feeding.
The Cost Reality: Significant Financial Barrier to Access
The major limitation of clascoterone isn’t efficacy or safety—it’s price. A 30-gram tube of Winlevi retails for approximately $242.42, translating to roughly $8.08 per gram. Since typical treatment involves applying a pea-sized amount twice daily, one tube lasts approximately 3-4 weeks. This means annual costs can reach $5,899 per patient if paying out-of-pocket, assuming continuous year-round use. For comparison, generic tretinoin costs $20-50 for a 3-month supply, and benzoyl peroxide costs even less.
Clascoterone is therefore roughly 100-200 times more expensive than generic alternatives, even though those alternatives don’t offer the specific advantage of targeting androgens. Insurance coverage varies significantly. Some plans cover clascoterone, while others require prior authorization, deny claims based on cost, or only cover it if the patient has failed other treatments first. The American Academy of Dermatology’s 2024 guidelines conditionally recommend clascoterone for acne management—the “conditional” qualifier explicitly acknowledges the high cost as a barrier to recommending it universally or as first-line therapy. For many patients, affordability rather than efficacy becomes the deciding factor. Manufacturer assistance programs exist, but eligibility is typically limited to uninsured or low-income patients, and the application process can be lengthy.
Global Rollout: From FDA Approval to International Availability
Clascoterone’s journey to global availability has been gradual but steady. Following FDA approval in the United States in August 2020, the drug received approval in Canada in 2023, Australia in 2024, and New Zealand in 2024. More recently, regulatory agencies in the United Kingdom (2025) and the European Union (October 2025) granted marketing authorization. This staggered rollout reflects the different regulatory timelines and submission processes across countries, but it also indicates growing international recognition of clascoterone’s value.
Patients in the UK who had previously struggled to access clascoterone now have an option, though NHS coverage decisions are still being finalized. The global expansion matters because it signals confidence from multiple regulatory bodies in clascoterone’s safety and efficacy profile. However, availability and pricing vary dramatically by country. In some European markets, clascoterone is priced more competitively than in the United States, reflecting different healthcare systems and negotiating power. For international patients, this has created some disparities in access—those in countries with higher prices face the same affordability barriers as Americans.
Who Should Consider Clascoterone, and What Does the Future Hold?
Clascoterone is ideally suited for patients with moderate acne driven or worsened by androgens, particularly those who have either failed to respond adequately to conventional treatments or cannot tolerate them. It’s a reasonable option for someone with androgen-responsive acne who experiences significant irritation from retinoids or benzoyl peroxide. It’s also worth considering for women with hormonally-driven acne who want to avoid systemic treatments, and for men with persistent acne that hasn’t responded to conventional topical regimens. The key is that clascoterone works best when cost is not a prohibitive barrier and when acne is truly androgen-responsive.
Looking forward, the approval of clascoterone represents a paradigm shift in topical acne treatment—recognition that hormones matter and can be targeted locally. The next frontier likely includes research into combination therapies (clascoterone with retinoids or benzoyl peroxide), potential development of more affordable generics (currently patent-protected), and investigation in other androgen-driven skin conditions. As more patients gain access and real-world data accumulates, dermatologists will refine which patients benefit most. The drug may also spur development of other topical antiandrogens with more favorable pricing, though none have yet been approved.
Conclusion
Clascoterone is indeed the first topical antiandrogen approved for acne in both men and women, and its FDA approval in 2020 marked a genuine innovation in acne treatment. The clinical evidence supporting its efficacy is solid, with Phase 3 trials demonstrating meaningful lesion reduction in 1,440 subjects without significant systemic effects. The safety profile is remarkably favorable compared to many existing topical acne treatments, with minimal irritation and no concerning systemic hormonal changes. For the right patient, clascoterone offers a targeted, topical approach to addressing one of the root causes of acne.
The practical challenge remains cost and access. At nearly $6,000 annually, clascoterone is prohibitively expensive for many patients despite its demonstrated benefits. If you’re considering clascoterone, discuss with your dermatologist whether it’s appropriate for your specific acne type, explore insurance coverage options and manufacturer assistance programs, and consider whether combination therapy with less expensive agents might achieve similar results. For those with severe androgen-responsive acne who can access it affordably, clascoterone represents a meaningful advancement in dermatological care.
